Arlene Chow, a first-chair Chambers-ranked litigator and trial lawyer, advises companies in the life sciences, pharmaceutical, and healthcare industries on a full spectrum of patent and intellectual property matters. She serves as Global Vice Chair of the firm’s Healthcare & Life Sciences Industry Group.

Ms. Chow advises pharmaceutical and biotech companies and medical device manufacturers on IP and patent litigation matters. Leveraging her background in biochemistry, she is able to frame matters from the perspective of a judge or jury in order to achieve the best solutions for her clients. Ms. Chow thrives on interaction with scientific experts, both in-house and externally, and adeptly simplifies highly technical information for her clients. She also performs patent due diligence in support of the purchase or sale of drugs or royalty streams.

Ms. Chow has particular experience with matters related to small molecule and biologic drugs for the treatment of a diverse assortment of medical indications. She also regularly advises clients on matters involving a wide variety of medical devices and dosage forms.

Ms. Chow is a United States Patent and Trademark Office (USPTO) registered patent attorney, and one of only a handful of lawyers who has been first-chair not only in district court trials and hearings, but also federal circuit arguments, and inter partes review hearings before the USPTO.

Ms. Chow serves as Co-Chair of the firm’s Women Enriching Business (WEB) committee in the New York office. She was shortlisted in the 2021 LMG Life Sciences Awards as “General Patent Litigator of the Year for New York.”

Speaking Engagements

  • Life Sciences Patent Network Conference, November 2022
  • ACI Paragraph IV Disputes Master Symposium, September 2022
  • Keynote Speaker, Women's Health Innovation Summit, September 2022
  • Recently Filed ANDAs, Cases and PTAB Proceedings, Pharmaceutical Litigation Strategy Summit, September 2021

Ms. Chow’s experience includes advising:

  • BASF as lead counsel in district court against CSIRO and Nuseed, defeating claims in 13 patents with claim construction, invalidity, and co-ownership determinations at pre-trial and jury trial
  • Merck Sharpe & Dohme as lead counsel, successfully invalidating Pfizer patent claims relating to polysaccharide-protein conjugate vaccine formulations
  • Amgen as lead counsel for patent owner, obtaining favorable written decision in inter partes review proceedings and at the Federal Circuit relating to method of refolding biologic proteins
  • Merck Sharp & Dohme as lead counsel in Hatch-Waxman district court actions relating to diabetes drug
  • Biogen as lead counsel in Hatch-Waxman district court action relating to multiple sclerosis drug
  • Astellas as lead counsel in Hatch-Waxman district court actions relating to overactive bladder drug
  • Merck Animal Health as lead counsel, defending against district court and post grant review proceedings brought by Boehringer Ingelheim Animal Health relating to swine vaccine patents
  • Santen and Asahi Glass as lead counsel in multiple Hatch-Waxman and inter partes review proceedings, obtaining a favorable final decision upholding validity of glaucoma drug patent
  • Merck Sharpe & Dohme in inter partes review proceedings adverse to GSK relating to polysaccharide-protein conjugate vaccine formulations
  • Takeda as lead counsel, obtaining a permanent injunction in Hatch-Waxman bench trial on infringement and validity for anti-ulcer, anti-GERD drug
  • Depomed as lead counsel for patent owner, obtaining favorable written decisions in inter partes review proceedings and at the Federal Circuit involving controlled release gastric retentive technology
  • BASF as lead counsel in inter partes review proceeding adverse to Nuseed relating to transgenic plants making omega-3 fatty acids
  • Photoscribe, a laser manufacturer, obtaining noninfringement, invalidity, and inequitable conduct determinations at bench and jury trials
  • Qisda and BenQ, LCD monitor manufacturers, obtaining noninfringement determinations at ITC bench trial
  • Millennium, obtaining summary judgment of invalidity determination in relation to urine drug testing protocols

*Certain matters were handled prior to joining Latham

Bar Qualification

  • New York
  • US Patent and Trademark Office


  • J.D., Columbia Law School, 1998
  • BS (Molecular Biophysics and Biochemistry), Yale University, 1994